Koyfin Home > Directory > Health Care > Adma Biologics > Capital Expenditures

Adma Biologics Capital Expenditures Chart (ADMA)

Adma Biologics annual/quarterly Capital Expenditures from 2010 to 2020.
  • Adma Biologics Capital Expenditures for the quarter ending June 06, 2020 was $-4m a 52.69% decrease of -2m year over year
  • Adma Biologics Capital Expenditures for the last 12 months ending June 06, 2020 was $-10m a 69.04% decrease of -7m year over year
  • Adma Biologics Annual Capital Expenditures for 2019 was $-4m a 45.02% decrease of -2m from 2018
  • Adma Biologics Annual Capital Expenditures for 2018 was $-2m a -27.71% increase of 1m from 2017
  • Adma Biologics Annual Capital Expenditures for 2017 was $-3m a 97.26% decrease of -3m from 2016
Other Cash Flow Metrics:
  • Adma Biologics Cash Flow from Operations for the quarter ending December 12, 2018 was $-19m a 12.55% decrease of -2m year over year
  • Adma Biologics Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-14m a 28.03% decrease of -4m year over year
  • Adma Biologics Total Revenue for the quarter ending September 09, 2018 was $4m a -183.74% decrease of -8m year over year
View Chart On Koyfin

Quarterly ADMA Capital Expenditures Data

06/2020$-4m
03/2020$-2m
12/2019$-2m
09/2019$-2m
06/2019$0m
03/2019$0m
12/2018$-1m
09/2018$0m
06/2018$0m
03/2018$-1m

Annual ADMA Capital Expenditures Data

2019$-4m
2018$-2m
2017$-3m
2016$0m
2015$0m
2014$-2m
2013$0m
2012$0m
2011$0m
2010$0m